IngenOx is a clinical stage company developing innovative drugs and vaccines aimed at re-invigorating the immune response to the most difficult cancers, often referred to as cold tumours. The company was created following the merger of two University of Oxford spinouts - Argonaut Therapeutics (an OSE portfolio company) and Celleron Therapeutics - in December 2022.